MCID: SYS003
MIFTS: 43

Systolic Heart Failure malady

Categories: Cardiovascular diseases

Aliases & Classifications for Systolic Heart Failure

Aliases & Descriptions for Systolic Heart Failure:

Name: Systolic Heart Failure 12 14
Heart Failure, Systolic 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9651
ICD10 33 I50.20
ICD9CM 35 428.2 428.20
MeSH 42 D054143
SNOMED-CT 64 417996009
UMLS 69 C1135191

Summaries for Systolic Heart Failure

MalaCards based summary : Systolic Heart Failure, also known as heart failure, systolic, is related to heart disease and myocardial infarction. An important gene associated with Systolic Heart Failure is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Dilated cardiomyopathy and A-beta Pathways: Uptake and Degradation. The drugs Nitric Oxide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Systolic Heart Failure

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
id Related Disease Score Top Affiliating Genes
1 heart disease 29.9 ACE CRP
2 myocardial infarction 28.5 ACE ADRB1 CRP CST3 IL6 MMP2
3 inferolateral myocardial infarct 10.3 ACE NPPB
4 atrial fibrillation 10.3
5 syringomelia hyperkeratosis 10.2 ACE NPPB
6 glucosephosphate dehydrogenase deficiency 10.2 IL6 NPPB
7 eastern equine encephalitis 10.2 ACE NPPB
8 preaxial polydactyly of fingers 10.2 ACE IL6
9 lymphocytic colitis 10.2 ACE MMP2
10 neonatal hypoxic and ischemic brain injury 10.2 IL6 MMP2
11 median neuropathy 10.2 ACE NPPB
12 prostate neuroendocrine neoplasm 10.2 ACE NR3C2
13 citrulline transport defect 10.2 CRP NPPB
14 iron metabolism disease 10.2 ACE CRP
15 artery disease 10.2
16 opiate dependence 10.2 ACE CST3
17 eye degenerative disease 10.1 ACE MMP2 NPPB
18 coloboma of iris 10.1 CRP IL6
19 cutaneous sclerosis 10.1 CRP IL6
20 porencephaly 2 10.1 ACE CST3
21 shoulder impingement syndrome 10.1 CRP IL6
22 trichomalacia 10.1 IL6 MMP2
23 myopia 10.1 ACE CST3
24 neutrophilia, hereditary 10.1 CRP IL6
25 iida kannari syndrome 10.1 ACE NPPB NR3C2
26 swine influenza 10.1 CRP IL6
27 coronary artery disease 10.1
28 cardiac tuberculosis 10.1 CRP IL6
29 cataract, total congenital 10.1 CRP IL6
30 laryngotracheoesophageal cleft type 2 10.1 CRP IL6
31 gastric lymphoma 10.1 CRP IL6
32 human immunodeficiency virus infectious disease 10.1 CRP IL6
33 hemangioma of spleen 10.1 CRP IL6
34 mixed eosinophil-basophil adenoma 10.1 CRP IL6
35 gastric dilatation 10.1 IL6 MMP2
36 sleep apnea 10.1
37 obesity 10.1
38 kidney disease 10.1
39 cardiomyopathy 10.1
40 retinal degeneration 10.1 CRP IL6
41 nodular nonsuppurative panniculitis 10.1 CRP IL6
42 sleep disorder 10.1
43 deafness, autosomal recessive 79 10.1 ACE CRP NPPB
44 familial periodic paralysis 10.1 ACE CRP NPPB
45 pyelonephritis 10.1 ACE CRP NPPB
46 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.1 ACE CRP NPPB
47 unilateral multicystic dysplastic kidney 10.0 CRP IL6 NPPB
48 cicatricial lagophthalmos 10.0 CRP IL6
49 pancreas lymphoma 10.0 CRP IL6 NPPB
50 urinary bladder posterior wall cancer 10.0 CRP IL6 NPPB

Graphical network of the top 20 diseases related to Systolic Heart Failure:



Diseases related to Systolic Heart Failure

Symptoms & Phenotypes for Systolic Heart Failure

MGI Mouse Phenotypes related to Systolic Heart Failure:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 ADRB1 CORIN CRP CST3 IL6 MMP2
2 homeostasis/metabolism MP:0005376 9.56 ACE ADRB1 CORIN CRP CST3 IL6
3 muscle MP:0005369 9.1 ADRB1 CORIN CST3 IL6 MMP2 NR3C2

Drugs & Therapeutics for Systolic Heart Failure

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 519)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
2
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
3
Verapamil Approved Phase 4 52-53-9 2520
4
Digoxin Approved Phase 4,Phase 2,Phase 3,Phase 1 20830-75-5 30322 2724385
5
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
6
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
7
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
8
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 72956-09-3 2585
9
Bisoprolol Approved Phase 4 66722-44-9 2405
10
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
11
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
12
Ticlopidine Approved Phase 4 55142-85-3 5472
13
Dobutamine Approved Phase 4,Phase 2 34368-04-2 36811
14
Abciximab Approved Phase 4 143653-53-6
15
Deferiprone Approved Phase 4 30652-11-0 2972
16
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
17
Fluorouracil Approved Phase 4 51-21-8 3385
18
Epirubicin Approved Phase 4 56420-45-2 41867
19
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
20
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
21
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
22
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
23
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2 54-31-9 3440
24
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
25
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
26
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
27
Captopril Approved Phase 4,Phase 1 62571-86-2 44093
28
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 1 83915-83-7 5362119
29
Ramipril Approved Phase 4,Phase 3,Phase 2 87333-19-5 5362129
30
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
31
Trandolapril Approved Phase 4 87679-37-6 5484727
32
Losartan Approved Phase 4,Phase 1 114798-26-4 3961
33
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
34
Benazepril Approved, Investigational Phase 4,Phase 3 86541-75-5 5362124
35
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
36
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
37
Eplerenone Approved Phase 4,Phase 3,Phase 2,Phase 1 107724-20-9 150310 443872
38
Chlorthalidone Approved Phase 4,Phase 3 77-36-1 2732
39
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
40
Doxazosin Approved Phase 4 74191-85-8 3157
41
Nebivolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 152520-56-4, 99200-09-6, 118457-14-0 71301
42
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
43
Allopurinol Approved Phase 4 315-30-0 2094
44 sodium fluoride Approved Phase 4 7681-49-4
45
Amiloride Approved Phase 4,Phase 1 2016-88-8, 2609-46-3 16231
46
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
47
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
48
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 171596-29-5 110635
49
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
50
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418

Interventional clinical trials:

(show top 50) (show all 764)
id Name Status NCT ID Phase
1 Platelet Inhibition in Patients With Systolic Heart Failure Unknown status NCT01765400 Phase 4
2 Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4
3 Medtronic South Asian Systolic Heart Failure Registry Unknown status NCT01434615 Phase 4
4 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4
5 Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat Unknown status NCT01612260 Phase 4
6 Danish ICD Study in Patients With Dilated Cardiomyopathy Unknown status NCT00542945 Phase 4
7 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure Unknown status NCT01156207 Phase 4
8 Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4
9 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
10 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
11 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
12 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4
13 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4
14 A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial) Unknown status NCT01589380 Phase 4
15 Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major Unknown status NCT00103753 Phase 4
16 Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction. Unknown status NCT01080638 Phase 4
17 Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure Completed NCT02401126 Phase 4
18 A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea Completed NCT01074307 Phase 4
19 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
20 A Trial of Thiamin Supplementation in Patients With Heart Failure Completed NCT00959075 Phase 4
21 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4
22 A Study Of The Usage Of Statins In A Community Heart Failure Population Completed NCT00795912 Phase 4
23 Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone Completed NCT00391846 Phase 4
24 Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure Completed NCT01699776 Phase 4
25 Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure Completed NCT01261065 Phase 4
26 The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure Completed NCT00082589 Phase 4
27 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure Completed NCT00733343 Phase 4
28 To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure Completed NCT01682564 Phase 4
29 Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement Completed NCT01711281 Phase 4
30 Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT) Completed NCT00677014 Phase 4
31 SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI) Completed NCT01046838 Phase 4
32 Effect of Passive Exercise on Systemic Endothelial Function in Elderly Patients With Chronic Heart Failure Completed NCT00733161 Phase 4
33 A Study of Triple-site Ventricular Pacing in Patients Who Have Not Responded to Conventional Dual Ventricular Site Cardiac Resynchronization Therapy Completed NCT00941850 Phase 4
34 Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy. Completed NCT00489177 Phase 4
35 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4
36 The TRUST Trial - CardioVascular Imaging ECHO Completed NCT02832960 Phase 4
37 Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure Completed NCT00115726 Phase 4
38 Effects of Carvedilol on Health Outcomes in Heart Failure Completed NCT00381030 Phase 4
39 Assessment of Hemodynamic Response in Cardiopulmonary Bypass Graft After Cardiopulmonary Bypass Using Transesophegeal Echocardiography Completed NCT01616069 Phase 4
40 Valsartan in Elderly Isolated Systolic Hypertension Study Completed NCT00151229 Phase 4
41 Statin Therapy in Heart Failure: Potential Mechanisms of Benefit Completed NCT00233480 Phase 4
42 Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients. Completed NCT01104558 Phase 4
43 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4
44 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4
45 Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation Completed NCT01164592 Phase 4
46 Clinical Evaluation on Advanced Resynchronization Completed NCT00658203 Phase 4
47 Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis Completed NCT01060020 Phase 4
48 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery Completed NCT00397514 Phase 4
49 CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI Completed NCT00162331 Phase 4
50 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed NCT00134160 Phase 4

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Genetic Tests for Systolic Heart Failure

Anatomical Context for Systolic Heart Failure

MalaCards organs/tissues related to Systolic Heart Failure:

39
Heart, Testes, Brain, Kidney, Endothelial, Neutrophil, Bone

Publications for Systolic Heart Failure

Articles related to Systolic Heart Failure:

(show top 50) (show all 614)
id Title Authors Year
1
Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. ( 27867115 )
2017
2
Prevalence of airflow obstruction in patients with stable systolic heart failure. ( 28061834 )
2017
3
The longitudinal relationship between six-minute walk test and cardiopulmonary exercise testing, and association with symptoms in systolic heart failure: Analysis from the ESCAPE trial. ( 28065659 )
2017
4
Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. ( 28068900 )
2017
5
Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). ( 27884420 )
2017
6
The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study. ( 27865188 )
2017
7
Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure. ( 27979033 )
2017
8
Effect of Spironolactone on Plasma Apelin-12 Levels in Patients with Chronic Systolic Heart Failure. ( 27899856 )
2016
9
The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure. ( 27039084 )
2016
10
Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. ( 27574749 )
2016
11
Isokinetic Torque Timing Parameters and Ceramides as Markers of Muscle Dysfunction in Systolic Heart Failure. ( 27039968 )
2016
12
The prognostic impact and optimal timing of the Patient Health Questionnaire depression screen on 4-year mortality among hospitalized patients with systolic heart failure. ( 27638965 )
2016
13
Immunosenescence in patients with chronic systolic heart failure. ( 26909541 )
2016
14
Arrhythmias and Electrocardiographic Changes in Systolic Heart Failure. ( 27213140 )
2016
15
Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure? ( 27650467 )
2016
16
Acute systolic heart failure and uncontrolled hypertension: what is the missing link? ( 27455906 )
2016
17
Functional characterization of human umbilical cord-derived mesenchymal stem cells for treatment of systolic heart failure. ( 27882158 )
2016
18
Clinical Benefits of Stem Cells for Chronic Symptomatic Systolic Heart Failure: A Systematic Review of the Existing Data and Ongoing Trials. ( 27931504 )
2016
19
Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? ( 27568794 )
2016
20
Exercise Ventilation in COPD: Influence of Systolic Heart Failure. ( 27172093 )
2016
21
Early improvement of symptoms using LCZ696 in a patient with systolic heart failure and a reduced ejection fraction: a case report. ( 27422865 )
2016
22
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. ( 27571011 )
2016
23
Survival risk of salivary cortisol and serum N-terminal pro-hormone B-type natriuretic peptide in patients with systolic heart failure. ( 27138698 )
2016
24
LV mechanical dispersion as a predictor of ventricular arrhythmia in patients with advanced systolic heart failure : A pilot study. ( 26883898 )
2016
25
In nonischemic systolic heart failure, prophylactic ICDs did not reduce all-cause mortality compared with usual care. ( 27842392 )
2016
26
Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. ( 26892413 )
2016
27
Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease. ( 27780557 )
2016
28
Improving performance of an accountable care organization on a quality measure assessing I^-blocker use in systolic heart failure. ( 27543597 )
2016
29
Sympathetic Nerve Activity Efferent Drive and Beta-Blocker Treatmenta88- Effect of Interaction in Systolic Heart Failure. ( 27616450 )
2016
30
Vitamin D levels predict the response to cardiac resynchronization therapy in patients with systolic heart failure. ( 28045413 )
2016
31
Left ventricular partitioning in systolic heart failure subjects: addressing a mechanistic void with current therapies. ( 27174122 )
2016
32
Furosemide Prescription During the Dry State Is a Predictor of Long-Term Survival of Stable, Optimally Medicated Patients With Systolic Heart Failure. ( 27784799 )
2016
33
Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients. ( 27690339 )
2016
34
Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial. ( 26873681 )
2016
35
Positive Impact of Continuous-Flow Left Ventricular Assist Device Implantation on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Advanced Chronic Systolic Heart Failure. ( 27779786 )
2016
36
Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. ( 27579829 )
2016
37
Autoantibodies Specifically Against I^1 Adrenergic Receptors and Adverse Clinical Outcome in Patients With Chronic Systolic Heart Failure in the I^-Blocker Era: The Importance of Immunoglobulin G3 Subclass. ( 26997620 )
2016
38
Adaptive Servo-Ventilation and Central Apnea Associated with Systolic Heart Failure. ( 26888594 )
2016
39
Characteristics and outcomes of patients with acute systolic heart failure discharged within 48hours: A qualification for "observation status" hospital admission. ( 27537738 )
2016
40
The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. ( 27465132 )
2016
41
Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With TheA Guidelines-Heart Failure Program. ( 27179827 )
2016
42
Impact of Chronic Total Occlusion of the CoronaryA Artery on Long-TermA Prognosis in Patients WithA Ischemic Systolic Heart Failure: Insights From the COMMIT-HF Registry. ( 27609252 )
2016
43
Ratio of transmitral early filling velocity to early diastolic strain rate predicts outcomes in patients with systolic heart failure. ( 26896414 )
2016
44
Sympathetic nervous system, systolic heart failure, and central sleep apnea: Are we about to find the missing link? ( 27457530 )
2016
45
Mortality in systolic heart failure revisited: Ischemic versus non-ischemic cardiomyopathy. ( 27599385 )
2016
46
TSOC-HFrEF Registry: A Registry of Hospitalized Patients with Decompensated Systolic Heart Failure: Description of Population and Management. ( 27471353 )
2016
47
Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study. ( 27647775 )
2016
48
The relationship between serum lectin-like oxidized LDL receptor-1 levels and systolic heart failure. ( 27090040 )
2016
49
Sleep-Disordered Breathing Exacerbates Muscle Vasoconstriction and Sympathetic Neural Activation in Patients with Systolic Heart Failure. ( 28029639 )
2016
50
Don't expect left ventricular reverse remodeling after cardiac resynchronization therapy in patients with systolic heart failure and atrioventricular block: A multicenter study. ( 27420585 )
2016

Variations for Systolic Heart Failure

Expression for Systolic Heart Failure

Search GEO for disease gene expression data for Systolic Heart Failure.

Pathways for Systolic Heart Failure

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.57 ACE ADRB1 IL6
2 10.87 ACE MMP2
3 10.79 IL6 MMP2
4 10.23 CRP IL6
5 10.21 ACE CST3 MMP2

GO Terms for Systolic Heart Failure

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 ACE CRP CST3 IL6 MMP2 NPPB
2 extracellular region GO:0005576 9.17 ACE CORIN CRP CST3 IL6 MMP2

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.54 CST3 IL6 MMP2
2 embryo implantation GO:0007566 9.48 CST3 MMP2
3 response to cold GO:0009409 9.46 ADRB1 IL6
4 positive regulation of DNA replication GO:0045740 9.43 CST3 IL6
5 acute-phase response GO:0006953 9.4 CRP IL6
6 regulation of vasodilation GO:0042312 9.32 ACE NPPB
7 neutrophil mediated immunity GO:0002446 9.26 ACE IL6
8 negative regulation of lipid storage GO:0010888 9.16 CRP IL6
9 regulation of blood vessel diameter GO:0097746 8.96 ACE NPPB
10 regulation of blood pressure GO:0008217 8.8 ACE CORIN NPPB

Sources for Systolic Heart Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....